Population Pharmacokinetics of Doxycycline in Children

Elizabeth J Thompson1, Huali Wu2, Chiara Melloni2

  • 1Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.

Insights

Doxycycline dosing for children under 8 years old is not well-established. This study found that pharmacokinetic parameters for doxycycline in children are similar to adults, suggesting similar per kg dosing may be appropriate for younger children.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Development

Background:

  • Doxycycline is FDA-approved for children over 8 years old.
  • Limited pharmacokinetic data exists for doxycycline in children 8 years and younger.
  • Off-label use in younger children is common for severe infections despite tooth staining risks.

Purpose of the Study:

  • To characterize doxycycline pharmacokinetics (PK) in children aged 0-18 years.
  • To evaluate the impact of age, obesity, and fasting on doxycycline PK.
  • To inform dosing guidelines for pediatric populations.

Main Methods:

  • Developed a population pharmacokinetic model using plasma samples from 47 pediatric patients.
  • Included 14 participants aged 8 years and younger.
  • Analyzed data from oral and intravenous doxycycline doses.

Main Results:

  • A one-compartment PK model showed doxycycline clearance (3.32 L/h/70 kg) and volume (96.8 L/70kg) comparable to adults.
  • Estimated bioavailability was 89.6%, consistent with adult data.
  • No significant differences in allometrically scaled PK parameters were found between children ≤8 years and >8 to ≤18 years.

Conclusions:

  • Pediatric doxycycline pharmacokinetics are similar to adult values.
  • Current per kg dosing may be appropriate for children 8 years and younger.
  • Obesity and fasting status did not significantly impact doxycycline PK in this cohort.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
258
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
249
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
196
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
258
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
155